Teva Pharmaceutical Industries (NYSE:TEVA) Director Roberto Mignone Sells 77,400 Shares of Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Director Roberto Mignone sold 77,400 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the transaction, the director directly owned 367,600 shares of the company’s stock, valued at $11,116,224. The trade was a 17.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Roberto Mignone also recently made the following trade(s):

• On Thursday, November 6th, Roberto Mignone sold 200,000 shares of Teva Pharmaceutical Industries stock. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $30.28 on Friday. The company has a 50-day simple moving average of $24.23 and a 200-day simple moving average of $19.95. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. The company has a market cap of $34.73 billion, a PE ratio of 50.47, a price-to-earnings-growth ratio of 1.79 and a beta of 0.67. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $30.44.

Wall Street Analyst Weigh In

Several research analysts have weighed in on TEVA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. The Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, December 8th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Wall Street Zen cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 13th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $31.13.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently added to or reduced their stakes in TEVA. Cromwell Holdings LLC increased its stake in Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after acquiring an additional 629 shares during the last quarter. Advisors Asset Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $41,000. Rothschild Investment LLC increased its position in Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after purchasing an additional 1,348 shares in the last quarter. JFS Wealth Advisors LLC increased its position in Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after purchasing an additional 2,000 shares in the last quarter. Finally, LRI Investments LLC raised its holdings in Teva Pharmaceutical Industries by 246.0% in the third quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock valued at $57,000 after buying an additional 2,000 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.